Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas

Alba Ariela Brandes, Elvira Scelzi, Paolo Zampieri, Alberto Rigon, Antonino Rotilio, Pietro Amista, Franco Berti, Mario V. Fiorentino

Research output: Contribution to journalArticlepeer-review

Abstract

A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.

Original languageEnglish
Pages (from-to)364-367
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number4
DOIs
Publication statusPublished - Aug 1997

Keywords

  • BCNU
  • Central nervous system tumors
  • Chemotherapy
  • Cytoreductive surgery
  • Interferon

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas'. Together they form a unique fingerprint.

Cite this